Toxin-nanoparticle combo inhibits brain cancer invasion while imaging tumors



Women who have decided that they do not want to ever become pregnant often select permanent sterilization. Patients who opt for hysteroscopic sterilization need to understand that this noninvasive procedure, which offers rapid recovery and return to daily activities, also consists of 2 parts: placement of the device and the confirmatory hysterosalpingogram (HSG). Both parts

Full Post: Is hysteroscopic sterilization permanent for women?

Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert this potentially beneficial effect.

Miqin Zhang, Ph.D., principal investigator of the Nanotechnology Platform for Pediatric Brain Cancer Imaging and Therapy project, and her colleagues had shown previously (click here and here to see earlier stories) that chlorotoxin, a small peptide toxin produced by the death stalker scorpion, is highly effective as a tumor-targeting agent when chemically linked to a variety of nanoparticles. In this work, whose results appear in the journal Small, Dr. Zhang’s team linked chlorotoxin to magnetic iron oxide nanoparticles, which can act as tumor imaging agents in conjunction with magnetic resonance imaging (MRI).

When added to glioblastoma cells growing in culture, the chlorotoxin-targeted nanoparticles were rapidly taken up by the tumor cells. This internalization occurs when chlorotoxin binds to a surface protein known as MMP-2 that is overexpressed by many highly invasive tumors, including glioblastoma. As a consequence of nanoparticle binding and internalization, the amount of MMP-2 remaining on the surface of the tumor cells drops significantly, which greatly reduces the invasive properties of the treated cells.

Quantifying this effect, the investigators showed that the nanoparticle produced a 98% inhibition of cell invasiveness. By way of comparison, invasiveness fell by less than 50% when cells were treated with chlorotoxin alone.

This work, which was detailed in the paper “Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles,” was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. Investigators from the National Cancer Institute and Johns Hopkins University also participated in this study. An abstract of this paper is available at the journal’s Web site. View abstract

http://nano.cancer.gov

Link




Given that cancer is a disease caused by gene mutations, cancer researchers have been striving to develop gene therapies aimed at correcting these mutations. However, these efforts have been hobbled by the difficulty in safely and efficiently delivering anticancer genes to tumors. Nanoparticles, however, may solve these delivery issues, and two recently published studies, using

Full Post: Targeted nanoparticles deliver therapeutic DNA to cancer cells



Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on

Full Post: Artificial antibody delivers nanoparticles to tumors



A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells. The nanoparticles are composed of two different polymers and are decorated with a nucleic acid aptamer that binds to the tumor marker prostate-specific membrane antigen.

Full Post: Targeted nanoparticles boost platinum-based anticancer therapy



One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors. And although many if not most tumors are surrounded by leaky blood vessels, the

Full Post: Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy



One of the key steps in the development of any drug or imaging agent intended for human use is measurement of the adsorption, metabolism, and excretion of the drug. Quantifying this collection of pharmacological properties, known as ADME, is a challenging and time-consuming process that is even more difficult when the drug or imaging

Full Post: Measuring nanoparticle behavior in the body using MRI